Funded Biotechnology Startups in Belgium

The three largest are AgomAb Therapeutics' $89M Series D (Ghent, October 2024), Precirix's $88M Series B (Brussels, March 2022), and Augustine Therapeutics' $84M Series A (Leuven, March 2025). Confo Therapeutics (Brussels) raised $65M in a July 2024 Series B, and EyeD Pharma (Liège) closed a $51M venture round in December 2021.

Oost-Vlaanderen is the dominant hub, with eleven companies clustered around Ghent and the Zwijnaarde research zone—including Animab, AgomAb Therapeutics, Dualyx, MRM Health, Allegro Biotech, FOx Biosystems, Zymofix, ExeVir Bio, RheaVita, and 4Tissue. Mont-saint-guibert in Brabant Wallon is the next-largest single-location cluster, with four companies: Cognivia, EsoBiotec, Celyad, and Novadip Biosciences.

Nine records carry a 'Series Unknown' label, reflecting rounds where the stage was not disclosed. Among named stages, both Series A and Series B each account for five rounds: Series A covers Augustine Therapeutics, EsoBiotec, Santero Therapeutics, Dualyx, and DeuterOncology; Series B includes Animab, Confo Therapeutics, Novadip Biosciences, eTheRNA, and Precirix. There are also three seed rounds, two Series D deals, and one post-IPO equity raise.

Four rounds in the data closed in 2025: Augustine Therapeutics' $84M Series A (Leuven, March), Animab's $12M Series B (Gent, July), 4Tissue's $1M Seed (Zwijnaarde, February), and Tavira Therapeutics' $360K round (Limburg, February). Augustine Therapeutics' deal is the largest single disclosed raise among those four 2025 records.

Three seed rounds appear in the dataset: Allegro Biotech ($6M, Ghent, April 2023), Zymofix ($2M, Wondelgem, November 2024), and 4Tissue ($1M, Zwijnaarde, February 2025). A $100K pre-seed for Vivagran (Oost-Vlaanderen, May 2024) rounds out the earliest-stage deals; all four companies are located in Oost-Vlaanderen.